New eczema ointment shows promise in Late-Stage trial
NCT ID NCT07185282
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 3 study tested MH004 ointment in 375 adolescents and adults with mild to moderate atopic dermatitis (eczema). Participants applied the ointment or a placebo twice daily for 4 weeks, followed by a 44-week safety extension. The main goals were to see if the ointment could clear or nearly clear the skin and reduce eczema severity by at least 75%.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MH004 ointment
What this could lead to
If successful, this could provide a new topical treatment option for people with mild to moderate atopic dermatitis, helping to clear skin and reduce eczema severity.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The ointment may not work better than a placebo, and long-term safety data are still being analyzed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, China